1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
Supplementary Table 11. Dose effect analyses of mobilization
measured by different biomarkers. Correlation between
plerixafor dose and mobilization of absolute FISH+ cells,
absolute CD34+ cells, and WBCs for 44 patients on trial shows
that plerixafor doses used in this study do not influence the
amount of mobilization in the patients studied. For each
biomarker, mobilization was defined as the peak measurement
among days -8, -7, -6 with the baseline biomarker measurement
taken on day -9. The primary variable used in each linear regression
model is the difference between peak and baseline measurement,
specifically Y = (peak measurement) – (baseline measurement).
Linear regression was used to assess the relationship between each
of the transformed biomarker mobilization variables and dose of
plerixafor. Due to the skewness of some of the distributions of the
biomarker variables, the Box-Cox transformation Y  (Y - 1)/ for
 not equal to 0, and Y  log(Y) for  = 0 was used for each
biomarker measurement to obtain approximate normality. The
Cramer-von Mises test of normality was conducted for each the
transformed variables. Linear regression was used to assess the
relationship between each transformed biomarker mobilization
variable Y, as defined above, and dose. Doses are reported in μg/kg.
For absolute blast count, the variable was dichotomized into two
categories: absolute blast=0 vs. absolute blast >0 and logistic
regression was used.
Biomarker
Variable
Estimate (std error)
p-value
Intercept (Dose 240)
8.17 (0.30)
Dose 80 (vs. Dose 240)
-0.27 (0.72)
0.71
Dose 160 (vs. Dose 240)
-0.84 (0.64)
0.21
Intercept (Dose 240)
5.06 (0.34)
Dose 80 (vs. Dose 240)
1.37 (1.01)
0.18
Dose 160 (vs. Dose 240)
1.29 (0.79)
0.11
Absolute FISH+
Absolute CD34+
WBCs
Intercept (Dose 240)
2.45 (0.21)
Dose 80 (vs. Dose 240)
-0.23 (0.63)
0.72
Dose 160 (vs. Dose 240)
-0.01 (0.50)
0.99
Intercept (Dose 240)
0.89 (0.87)
Absolute blast (>0 vs. =0)
26
27
Dose 80 (vs. Dose 240)
1.03 (1.65)
0.53
Dose 160 (vs. Dose 240)
-0.60 (1.15)
0.60